The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. [electronic resource]
Producer: 20161107Description: 745-58 p. digitalISSN:- 1949-2553
- Antineoplastic Agents -- pharmacology
- Biliary Tract Neoplasms -- genetics
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Cisplatin -- pharmacology
- Dose-Response Relationship, Drug
- Drug Synergism
- Flow Cytometry
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Gene Expression Regulation, Neoplastic -- drug effects
- Heterocyclic Compounds, 2-Ring -- pharmacology
- Humans
- Immunohistochemistry
- Neoplastic Stem Cells -- drug effects
- Polycomb Repressive Complex 1 -- antagonists & inhibitors
- Reverse Transcriptase Polymerase Chain Reaction
- Thiazoles -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.